The effect of glucose variability on the risk of microvascular complications in type 1 diabetes

被引:252
作者
Kilpatrick, Eric S.
Rigby, Alan S.
Atkin, Stephen L.
机构
[1] Hull Royal Infirm, Dept Clin Biochem, Kingston Upon Hull HU3 2JZ, N Humberside, England
[2] Hull York Med Sch, Dept Diabet, Hull, PQ, Canada
关键词
D O I
10.2337/dc06-0293
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - it is not known whether glycemic instability may confer a risk of microvascular complications that is in addition to that predicted by the mean blood glucose (MBG) value alone. This study has analyzed data from the Diabetes Control and Complications Trial (DCCT) to assess the effect of glucose variability on the risk of retinopathy and nephropathy in patients with type I diabetes. RESEARCH DESIGN AND METHODS - Pre- and postprandial seven-point glucose profiles were collected quarterly during the DCCT in 1,441 individuals. The mean area under the curve glucose and the SD of glucose variability within 24 h and between visits were compared with the risk of retinopathy and nephropathy, having adjusted for age, sex, disease duration, treatment group, prevention cohort, and phase of treatment. RESULTS - Multivariate Cox regression showed that within-day and between-day variability in blood glucose around a patient's mean value has no influence on the development or progression of either retinopathy (P = 0.18 and P = 0.72, respectively) or nephropathy (P = 0.32 and P = 0.57). Neither preprandial (P = 0.18) nor postprandial (P = 0.31) glucose concentrations preferentially contribute to the probability of retinopathy. CONCLUSIONS - This study has shown that blood glucose variability does not appear to be an additional factor in the development of microvascular complications. Also, pre- and postprandial glucose values are equally predictive of the small-vessel complications of type I diabetes.
引用
收藏
页码:1486 / 1490
页数:5
相关论文
共 31 条
  • [1] Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
  • [2] American Diabetes Association, 2001, Diabetes Care, V24, P775
  • [3] [Anonymous], 1996, DIABETES, V45, P1289
  • [4] [Anonymous], 1995, DIABETES, V44, P968
  • [5] Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes
    Avignon, A
    Radauceanu, A
    Monnier, L
    [J]. DIABETES CARE, 1997, 20 (12) : 1822 - 1826
  • [6] High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men -: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study
    Balkau, B
    Shipley, M
    Jarrett, RJ
    Pyörälä, K
    Pyörälä, M
    Forhan, A
    Eschwège, E
    [J]. DIABETES CARE, 1998, 21 (03) : 360 - 367
  • [7] Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c
    Bastyr, EJ
    Stuart, CA
    Brodows, RG
    Schwartz, S
    Graf, CJ
    Zagar, A
    Robertson, KE
    [J]. DIABETES CARE, 2000, 23 (09) : 1236 - 1241
  • [8] Glucose tolerance and cardiovascular mortality -: Comparison of fasting and 2-hour diagnostic criteria
    Borch-Johnsen, K
    Neil, A
    Balkau, B
    Larsen, S
    Nissinen, A
    Pekkanen, J
    Tuomilehto, J
    Jousilahti, P
    Lindstrom, J
    Pyörälä, M
    Pyörälä, K
    Eschwege, E
    Gallus, G
    Garancini, MP
    Bouter, LM
    Dekker, JM
    Heine, RJ
    Nijpels, HG
    Stehouwer, CDA
    Feskens, EJM
    Kromhout, D
    Peltonen, M
    Pajak, A
    Eriksson, J
    Qiao, Q
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (03) : 397 - 405
  • [9] Postprandial hyperglycemia and diabetes complications - Is it time to treat?
    Ceriello, A
    [J]. DIABETES, 2005, 54 (01) : 1 - 7
  • [10] The relationship between glucose and incident cardiovascular events
    Coutinho, M
    Gerstein, HC
    Wang, Y
    Yusuf, S
    [J]. DIABETES CARE, 1999, 22 (02) : 233 - 240